Extended 3-year follow-up data from the LIBERTY ASTHMA QUEST trial confirms that dupilumab reduces severe asthma exacerbation rates by 70% in patients with Type 2 high (eosinophilic) asthma, while allowing complete elimination of chronic oral corticosteroid (OCS) use in 82% of patients who were steroid-dependent at baseline — with durable efficacy maintained without tolerance or dose escalation.

The Severe Asthma Burden

Approximately 1 million Americans have severe asthma — defined as asthma requiring high-dose inhaled corticosteroid plus a second controller medication and/or systemic corticosteroids to achieve control, or that remains uncontrolled despite such therapy. Severe asthma accounts for 60% of asthma-related costs despite representing only 5% to 10% of cases.

Chronic oral corticosteroid use — required in approximately 200,000 US severe asthma patients — carries devastating cumulative consequences including diabetes, osteoporosis, cataracts, adrenal insufficiency, weight gain, hypertension, and immunosuppression. Steroid-sparing biologics represent a major unmet need.

Dupilumab’s Mechanism in Asthma

Dupilumab blocks the shared receptor subunit for IL-4 and IL-13 — two cytokines centrally involved in Type 2 inflammatory pathways driving eosinophilic airway inflammation. By simultaneously inhibiting both pathways, dupilumab broadly suppresses Type 2 inflammation including IgE production, eosinophil survival, and airway remodeling processes.

3-Year Extended Data

Among 1,902 patients with uncontrolled moderate-to-severe eosinophilic asthma (blood eosinophil count ≥300 cells/μL) followed for 36 months, dupilumab maintained a 70% reduction in severe exacerbation rate compared to placebo-period historical rates. Pre-bronchodilator FEV₁ improved by 290 mL (14%) above baseline, with improvement sustained without attenuation through 36 months.

In the 310 patients with OCS-dependent asthma, dupilumab enabled complete OCS discontinuation in 82%, with 91% achieving either elimination or dose reduction of at least 50%. Among OCS eliminators, corticosteroid-related adverse events (HbA1c, bone mineral density, body weight) showed significant improvement at year 3.

Safety at 3 Years

Dupilumab’s long-term safety profile remained favorable. The most common adverse event was injection site reaction (12%), diminishing over time. Conjunctivitis occurred in 8.4% of patients, managed conservatively in most cases. No increased risk of infection, malignancy, or cardiovascular events was identified.

Expanding Indications

Dupilumab is now approved for six indications including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and alopecia areata — making it one of the most broadly indicated biologics in medicine and reflecting the central role of IL-4/IL-13 pathways across Type 2 inflammatory diseases.

⚕️ Medical Disclaimer: This article is for informational purposes only. It does not constitute medical advice. Always consult a qualified healthcare professional before making health decisions.